title: Characteristics of Escherichia coli sequence type 131 isolates that produce extended-spectrum β-lactamases: global distribution of the H30-Rx sublineage.
abstract: We designed a study to describe the characteristics of sequence type 131 (ST131) lineages, including the H30-Rx sublineage, among a global collection of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolates from 9 countries collected from 2000 to 2011. A total of 240 nonrepeat isolates from Canada, the United States, Brazil, the Netherlands, France, the United Arab Emirates (UAE), India, South Africa, and New Zealand were included. Established PCR, sequencing, and typing methods were used to define ST131 lineages, H30 and H30-Rx phylogenetic groups, gyrA and parC mutations, virotypes, and plasmid-mediated quinolone resistance determinants. The majority of the isolates produced CTX-M-15 with aac(6')-lb-cr, belonged to phylogenetic group B2, and were positive for the H30 lineage with the gyrA1AB and parC1aAB mutations. ST131 showed 15 distinct pulsotypes; 43% of the isolates belonged to four pulsotypes, with a global distribution. Seventy-five percent of the ST131 isolates belonged to H30-Rx; this sublineage was present in all the countries and was associated with multidrug resistance, blaCTX-M-15, aac(6')-lb-cr, and virotypes A and C. The H41 lineage was negative for the ST131 pabB allele-specific PCR. The multidrug-resistant H30-Rx sublineage poses an important public health threat due to its global distribution, association with virotype C, and high prevalence among ST131 isolates that produce CTX-M-15.
authors.affiliation: Division of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada Departments of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada.
authors.forename: Gisele
authors.initials: G
authors.lastname: Peirano
authors.affiliation: Centre for Infectious Disease Control, Epidemiology and Surveillance, Bilthoven, the Netherlands Reinier de Graaf Hospital, Delft, the Netherlands.
authors.forename: Akke K
authors.initials: AK
authors.lastname: van der Bij
authors.affiliation: Auckland District Health Board, Auckland, New Zealand University of Auckland, Auckland, New Zealand.
authors.forename: Joshua L
authors.initials: JL
authors.lastname: Freeman
authors.affiliation: Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland.
authors.forename: Laurent
authors.initials: L
authors.lastname: Poirel
authors.affiliation: Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland.
authors.forename: Patrice
authors.initials: P
authors.lastname: Nordmann
authors.affiliation: Microbiology, ACL Laboratories, Rosemont, Illinois, USA.
authors.forename: Michael
authors.initials: M
authors.lastname: Costello
authors.affiliation: Department of Microbiology, University of Washington, Seattle, Washington, USA.
authors.forename: Veronika L
authors.initials: VL
authors.lastname: Tchesnokova
authors.affiliation: Division of Microbiology, Calgary Laboratory Services, University of Calgary, Calgary, Alberta, Canada Departments of Pathology & Laboratory Medicine, University of Calgary, Calgary, Alberta, Canada Departments of Microbiology, Immunology, and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada johann.pitout@cls.ab.ca.
authors.forename: Johann D D
authors.initials: JD
authors.lastname: Pitout
mesh_terms: D018830:Adhesins, Escherichia coli / Q000235:genetics; D001434:Bacteriophage Typing; D027081:DNA Gyrase / Q000235:genetics; D027101:DNA Topoisomerase IV / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology* / Q000235:genetics*; D004927:Escherichia coli Infections / Q000382:microbiology; D036781:Fimbriae Proteins / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests; D010957:Plasmids / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics*
chemical_list: D018830:Adhesins, Escherichia coli; C058769:fimH protein, E coli; D036781:Fimbriae Proteins; D001618:beta-Lactamases; D027101:DNA Topoisomerase IV; D027081:DNA Gyrase
references.citation: Antimicrob Agents Chemother. 2013 Dec;57(12):6385-8
references.pmid: 24080662
references.citation: mBio. 2013 Dec 17;4(6):e00377-13
references.pmid: 24345742
references.citation: J Antimicrob Chemother. 2009 Aug;64(2):274-7
references.pmid: 19474064
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2846-51
references.pmid: 19380595
references.citation: Antimicrob Agents Chemother. 2006 Nov;50(11):3953-5
references.pmid: 16954321
references.citation: Lancet Infect Dis. 2008 Mar;8(3):159-66
references.pmid: 18291338
references.citation: J Antimicrob Chemother. 2008 Feb;61(2):273-81
references.pmid: 18077311
references.citation: Antimicrob Agents Chemother. 2012 Jul;56(7):3973-6
references.pmid: 22491693
references.citation: J Antimicrob Chemother. 2012 Feb;67(2):346-56
references.pmid: 22028202
references.citation: Antimicrob Agents Chemother. 2009 Jul;53(7):2733-9
references.pmid: 19398649
references.citation: Clin Infect Dis. 2013 Nov;57(9):1256-65
references.pmid: 23926176
references.citation: Antimicrob Agents Chemother. 2011 Jul;55(7):3576-8
references.pmid: 21502612
references.citation: Curr Opin Microbiol. 2006 Oct;9(5):466-75
references.pmid: 16942899
references.citation: Diagn Microbiol Infect Dis. 2011 Apr;69(4):449-53
references.pmid: 21396544
references.citation: J Infect Dis. 2013 Mar 15;207(6):919-28
references.pmid: 23288927
references.citation: J Clin Microbiol. 2005 Mar;43(3):1045-50
references.pmid: 15750058
references.citation: Diagn Microbiol Infect Dis. 2012 Apr;72(4):297-302
references.pmid: 22300954
references.citation: Antimicrob Agents Chemother. 2010 Mar;54(3):1327-30
references.pmid: 20047913
references.citation: PLoS One. 2014 Jan 30;9(1):e87025
references.pmid: 24498015
references.citation: Int J Antimicrob Agents. 2010 Jul;36(1):19-23
references.pmid: 20359869
references.citation: Clin Microbiol Infect. 2011 Jul;17(7):1039-43
references.pmid: 21722255
references.citation: Emerg Infect Dis. 2012 Apr;18(4):598-607
references.pmid: 22469129
references.citation: Antimicrob Agents Chemother. 2007 Apr;51(4):1281-6
references.pmid: 17283198
references.citation: Clin Microbiol Rev. 2005 Oct;18(4):657-86
references.pmid: 16223952
references.citation: Antimicrob Agents Chemother. 2006 Aug;50(8):2872-4
references.pmid: 16870791
references.citation: J Clin Microbiol. 2013 Oct;51(10):3358-67
references.pmid: 23926164
references.citation: Emerg Infect Dis. 2008 Feb;14(2):195-200
references.pmid: 18258110
references.citation: J Clin Microbiol. 2014 May;52(5):1358-65
references.pmid: 24501035
references.citation: Antimicrob Agents Chemother. 2008 Apr;52(4):1564-6
references.pmid: 18285488
references.citation: Appl Environ Microbiol. 2000 Oct;66(10):4555-8
references.pmid: 11010916
references.citation: J Clin Microbiol. 2012 Feb;50(2):294-9
references.pmid: 22162555
references.citation: Int J Antimicrob Agents. 2010 Apr;35(4):316-21
references.pmid: 20060273
references.citation: J Clin Microbiol. 1995 Sep;33(9):2233-9
references.pmid: 7494007